News

Repeal law that puts “FDA on the payroll of the industry,” says former NEJM editor

BMJ 2007; 334 doi: 10.1136/bmj.39140.456030.DB (Published 1 March 2007)
Cite this as: BMJ 2007;334:447.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Zosia Kmietowicz
  1. London

    The law that requires drug companies to pay “user fees” to the US Food and Drug Administration for every drug they submit for approval should not be renewed when it comes before Congress later this year, says a former editor of the New England Journal of Medicine.

    Writing an open editorial in the Boston Globe, Marcia Angell, who worked for the journal between 1979 and 2000, most recently as editor in chief, said that the Prescription Drug User Fee Act has, in effect, “put the FDA on the payroll of the industry it regulates” (www.boston.com, 26 Feb, “Taking back the FDA”).

    The act, which was passed by Congress in 1992, “put the fox in the chicken coop” and has changed the focus of the agency, which now serves the industry rather …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular